OpGen

Historical price data

OpGen's mission is to preserve the efficacy of antibiotics and improve patient outcomes by delivering rapid, precise diagnostic information to combat infectious diseases. Its core achievements include the FDA-cleared Acuitas AMR Gene Panel and the Unyvero multiplex PCR platform, which address critical needs in pneumonia, bloodstream, and urinary tract infections. The company's strategy integrates diagnostic testing with data analytics to support hospital antimicrobial stewardship and infection prevention programs, while its CapForce subsidiary represents a separate, non-core business initiative. OpGen faces the dual challenge of driving adoption in a competitive diagnostic market and achieving sustainable financial growth.

Integrated molecular diagnostics platform combining multiplex PCR-based tests (Acuitas, Unyvero) with proprietary bioinformatics and data analytics software (Acuitas Lighthouse®) to provide rapid pathogen identification, genetic resistance detection, and hospital surveillance.

OpGen competes with large-cap IVD leaders like bioMérieux (BioFire), Becton Dickinson, and Roche, which have greater sales forces and broader test menus. It differentiates with a specific focus on resistance genetics and integrated bioinformatics. However, its small size and limited resources make market penetration and sustained competition a significant challenge.